Lantern Pharma
LTRN
25 hedge funds and large institutions have $6.5M invested in Lantern Pharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
26% more capital invested
Capital invested by funds: $5.14M → $6.5M (+$1.36M)
19% more funds holding
Funds holding: 21 → 25 (+4)
0.63% more ownership
Funds ownership: 9.98% → 10.61% (+0.63%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$167K |
| 2 |
Renaissance Technologies
New York
|
+$105K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$77.5K |
| 4 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
+$72.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$71.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
-$154K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$17.4K |
| 3 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$13.4K |
| 4 |
WWM
Wolff Wiese Magana
Carslbad,
California
|
-$6.89K |
| 5 |
CWM
Cranbrook Wealth Management
Bloomfield Hills,
Michigan
|
-$3.46K |
LTRN Hedge Fund Activity: Q2 2023 in Review
25 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2023, worth a combined $6.5M — up 26% from $5.14M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LTRN positions and 1 closed out — a net gain of 4 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $167K. The largest seller was Carlson Capital, cutting an estimated $154K.
- 25 institutional investors held Lantern Pharma (LTRN) as of Q2 2023, up from 21 in Q1 2023.
- Funds reported $6.5M of Lantern Pharma stock for Q2 2023, up 26% quarter-over-quarter.
- 5 funds opened new Lantern Pharma positions in Q2 2023 and 1 closed out, a net change of +4 holders.
- The largest Lantern Pharma buyer in Q2 2023 was Geode Capital Management, an estimated $167K added.
- The largest Lantern Pharma seller in Q2 2023 was Carlson Capital, an estimated $154K sold.
Based on aggregated 13F filings for Q2 2023.